A nemia, as evidenced by reduced blood hemoglobin (or hematocrit) levels, frequently occurs in patients with chronic heart failure (HF), reportedly ranging from 9.0% 1 to 79.1%, 2 depending on the population studied, the severity of HF, and the criteria used for defining anemia. Reduced hemoglobin levels may contribute to worse outcomes through higher myocardial and peripheral oxygen demand, the development and accelerated progression of left ventricular (LV) hypertrophy, worsening of edema, and promotion of inflammation. 3 
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Several studies suggest that a lower hemoglobin level is associated with an increased risk of death in patients with HF, 4 -10 whereas others do not. 11, 12 Whether anemia predicts adverse outcomes independent of other prognostic factors, such as kidney dysfunction or other confounders, is not entirely clear. The generalizability of previous studies is limited by the inclusion of participants from clinical trials or other select populations; limited ethnic diversity; use of a single measure of hemoglobin or reliance on hemoglobin at the time of hospital admission, which may not reflect stable levels; lack of control for concomitant renal insufficiency or differences in therapies; and modest sample sizes. 8 -10,12-15 We examined a large, diverse HF population to determine the independent contributions of hemoglobin level and chronic kidney disease to the risks of death and HF-related hospitalization. We hypothesized that lower levels of hemoglobin and kidney function independently increase the risk of adverse events overall and in persons with reduced or preserved LV systolic function.
Methods

Source Population and Study Sample
All subjects were members of Kaiser Permanente of Northern California, a large, integrated, healthcare delivery system providing care for Ͼ3 million members. Its population is representative of local and statewide populations, with a slightly lower representation of the extremes of the socioeconomic spectrum and age. 16 The Kaiser Foundation Research Institute's institutional review board approved the study.
The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study analyzed data from the Kaiser Permanente chronic HF cohort, which included all adult members with diagnosed HF between January 1, 1996 and December 31, 2002. Subjects were included if they met Ն1 of the following criteria based on diagnoses from hospitalization, ambulatory visits, and/or emergency department databases: Ն1 hospitalization with a principal discharge diagnosis of HF (International Classification of Diseases, 9th revision [ICD-9] codes 398.91, 402.01, 402.11, 402.91, 428.0, 428.1, or 428.9; 21.9% of the cohort); 2 hospitalizations with a secondary discharge diagnosis of HF, for which the principal diagnosis was related to the disease (eg, coronary disease), 13.8%; Ն3 hospitalizations with a secondary discharge diagnosis of HF, 12.9%; Ն2 outpatient HF diagnoses, excluding those made in the emergency department, 45.7%; Ն3 emergency department diagnoses of HF, 0.001%; or Ն2 inpatient secondary diagnoses of HF (with any primary diagnosis) plus 1 outpatient diagnosis of HF (excluding that made in the emergency department), 5.7%. The index date was assigned at the first qualifying diagnosis date.
Hemoglobin Levels
We obtained outpatient hemoglobin measurements from health plan laboratory databases during the 12 months before a subject's entry into the cohort until the end of follow-up or censoring. We included outpatient measurements, which are more likely to represent steadystate concentrations.
Kidney Function
We used outpatient determinations of serum creatinine to estimate the glomerular filtration rate (GFR) according to the 4-variable Modification of Diet in Renal Disease equation. 17, 18 On the basis of prior work that has shown its predictive value for adverse outcomes in the general population, 19 estimated GFR (in units of mL · min Ϫ1 · 1.73 m Ϫ2 ) was categorized as Ն60, 45 to 59, 30 to 44, 15 to 29, Ͻ15 not receiving dialysis, and maintenance dialysis. 19 A GFR Ͼ60 mL · min Ϫ1 · 1.73 m Ϫ2 was not further delineated, given the higher degree of measurement error above this level. 20 Covariates Age, sex, and self-reported race/ethnicity were identified from health plan databases. Coexisting illnesses were ascertained from relevant inpatient and outpatient diagnoses or procedures according to ICD-9 codes, laboratory results, or medication prescriptions. This information was obtained from validated hospital discharge, ambulatory visit, laboratory, and pharmacy databases, as well as validated diabetes mellitus 22 and cancer 23 registries. We collected baseline and follow-up data on diagnoses of coronary disease (acute myocardial infarction, unstable angina, angina pectoris, coronary artery disease, percutaneous coronary intervention, and coronary artery bypass surgery), stroke/transient ischemic attack, peripheral arterial disease, diabetes, hypertension, cancer, thyroid disease, liver disease, lung disease, HIV infection, mitral and/or aortic valvular disease, dementia, depression, ventricular fibrillation/tachycardia, and atrial fibrillation/flutter (ICD-9 codes available on request). We ascertained information on LV systolic function status from HF management program records and hospitalization records. We defined reduced systolic function as an LV ejection fraction Յ40% or a qualitative description of "moderate or severely reduced" systolic function; preserved systolic function was defined by an LV ejection fraction Ͼ40% or a qualitative description of "normal or only mildly reduced" systolic function. 24 We controlled for use of the following medications during the 120 days before the index date and throughout follow-up, based on filled prescriptions found in pharmacy records: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, ␤-blockers, calcium channel blockers, statins, other lipid-lowering agents, spironolactone, direct vasodilators, and erythropoietin. Longitudinal medication use was estimated from drug refill patterns according to the calculated number of days supply for each prescription. For any 2 consecutive prescriptions, if the second prescription was filled within Յ30 days of the projected end date of the first, the patient was considered continually on the medication. If the second prescription was filled Ͼ30 days after the projected end date of the first, the patient was considered not taking the medication from day 31 until the start date of the next prescription. If 2 prescriptions for the same drug were filled on the same day, we used the longest estimated number of days supply to determine the end date.
Outcomes
Patients were censored at disenrollment or at the end of follow-up on December 31, 2002. Disenrollment was defined as a gap in membership of Ն90 days with no evidence of interim medical care. The primary outcomes were death from any cause and hospitalization for HF. Deaths were identified from health plan databases and state mortality files 25 through December 2002, which were the most recent data available at the time of the study. HF-related hospitalizations at health plan or nonnetwork facilities were identified from primary discharge diagnoses (ICD-9 codes 398.91, 402.01, 402.11, 402.91, and 428.x) found in hospitalization and billing claims databases. We have previously demonstrated 96% specificity for these codes 26 compared with Framingham clinical criteria based on medical records. 27 
Statistical Approach
Analyses were performed with SAS statistical software version 9.0 (SAS, Inc, Cary, NC). Comparisons of baseline characteristics by the presence or absence of anemia (defined as a baseline hemoglobin value Ͻ13 g/dL in men and Ͻ12 g/dL in women 28 ) were performed with a t test for continuous variables and the 2 test for categorical variables. Crude rates of death and hospitalization (dependent variables) by level of hemoglobin and estimated GFR (independent variables) were calculated from a Poisson regression, with generalized estimating equations to account for repeated measures of the independent variables within individuals. To examine the independent association between hemoglobin level, GFR, and adverse outcomes, we conducted extended Cox regression models with time-dependent covariates. Time-varying hemoglobin level and GFR categories were assigned from the last value carried forward approach. A hemoglobin value of 13.0 to 13.9 g/dL was used as the referent group after examination of crude outcome rates across hemoglobin levels. For recurrent nonfatal hospitalizations, we used a sandwich estimate of the variance-covariance matrix to obtain standard errors to accommodate the clustering of observations on subjects. 29 Additional variables selected for the final models included those known to be associated with outcomes and covariates that differed among subjects with or without anemia at baseline at PϽ0.05. We initially evaluated for the presence of interactions between hemoglobin level and either GFR or LV systolic function status with interaction terms in our multivariable analyses for both outcomes of interest. On the basis of these results, we next performed analyses stratified by baseline estimated GFR (Ն60, 45 to 59, 30 to 44, and Ͻ30 mL · min Ϫ1 · 1.73 m Ϫ2 ) in the entire cohort and in the presence of reduced versus preserved systolic function in those with known LV systolic function status. We further examined whether the time-dependent rate of change in hemoglobin level (g/dL per 6 person-months) provided any incremental information above the absolute hemoglobin level over time.
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Results
Baseline Characteristics and Follow-Up
A total of 59 772 adults with HF were identified, with a mean age of 72 years (range, 20 to 106 years); 46% were women, and 28% were nonwhite (Table 1) . At baseline, 42.6% of subjects were anemic by World Health Organization criteria. Patients with anemia at entry were more likely than those without anemia to be slightly older and male; to be a member of a minority group; to have a history of myocardial infarction, stroke, peripheral arterial disease, diabetes, hypertension, malignancy, unknown systolic function status, and reduced GFR; and to be receiving calcium channel blockers (Table 1) . Anemic patients were less likely to have known lung disease and atrial fibrillation/flutter and slightly less likely to receive an ACE inhibitor or diuretic compared with nonanemic patients. Of note, patients with an elevated hemoglobin value (Ն17 g/dL) were more likely than those without polycythemia to have diagnosed lung disease (34.8% versus 26.2%, respectively, PϽ0.001).
Hemoglobin Level, Kidney Function, and Outcomes
Overall, 23 901 deaths occurred during 146 454 person-years of follow-up (annual incidence, 20.0%). During a median follow-up of 2.07 years (interquartile range, 0.81 to 3.87), 85.7% of subjects had Ն1 additional outpatient hemoglobin measurement (mean number of tests, 7.9Ϯ10.0; median, 5 [interquartile range, 2 to 10]). The unadjusted rate of death increased with lower levels of hemoglobin, increasing from 11.7 per 100 person-years for a hemoglobin value of 13.0 to 13.9 g/dL to 73.9 per 100 person-years for a hemoglobin level Ͻ9.0 g/dL ( Figure 1A ). The rate of death did not change significantly for those with a hemoglobin value of 13.0 to 16.9 g/dL but was significantly increased for those with a hemoglobin value Ն17 g/dL. The crude rate of death was also elevated for those with reduced kidney function. The rate of death increased, from 11.0 per 100 person-years for subjects with an estimated GFR of Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 to a peak of 53.9 per 100 person-years for subjects with an estimated GFR Ͻ15 mL · min Ϫ1 · 1.73 m Ϫ2 and not receiving dialysis ( Figure 1B) .
A total of 37 192 hospitalizations for HF occurred among 23 719 cohort members (annual incidence, 25.4%). The crude rate of hospitalization was higher with lower levels of hemoglobin, increasing significantly below a hemoglobin value of 13.0 to 13.9 g/dL (19.6 per 100 person-years) to as high as 69.1 per 100 person-years for a hemoglobin value Ͻ9.0 g/dL. The rate of hospitalization was similar for those with hemoglobin levels of 13.0 to 16.9 g/dL but notably higher for those with hemoglobin values Ն17.0 g/dL ( Figure  2A ). The crude rate of HF-related hospitalization was also higher for those with poorer kidney function. The rate increased from 19.7 per 100 person-years for those with an estimated GFR Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 to 69.1 per 100 person-years for those with an estimated GFR Ͻ15 mL · min Ϫ1 · 1.73 m Ϫ2 and not receiving dialysis ( Figure 2B ).
Multivariable Analyses for Death and Hospitalization for HF
Hemoglobin Level
After adjustment for known confounders and kidney function, we found that compared with that for a hemoglobin value of 13.0 to 13.9 g/dL, the risk of death stayed relatively constant across hemoglobin levels of 14.0 to 16.9 g/dL, but the adjusted risk increased by 42% for hemoglobin values Ն17.0 g/dL (Table 2) . Below a hemoglobin value of 13.0 to 13.9 g/dL, there was a graded, independent increased risk of death, ranging from 16% for a hemoglobin value of 12.0 to 12.9 g/dL to 248% for a hemoglobin value of Ͻ9.0 g/dL (Table 2) . In separate analyses, the rate of change in hemoglobin level per 6 person-months was not significantly associated with death, after accounting for the absolute level of hemoglobin and other covariates (data not shown). We observed similar patterns between hemoglobin level and hospitalization for HF, although with smaller effect sizes. Compared with that for a hemoglobin value of 13.0 to 13.9 g/dL, there was no significant difference in the adjusted risk of hospitalization for a hemoglobin value of 14.0 to 16.9 g/dL, but the adjusted risk was significantly increased by 14% for a hemoglobin value Ն17.0 g/dL (Table 2) . Below a hemoglobin value of 13.0 to 13.9 g/dL, the adjusted risk of hospitalization increased by 12% for a hemoglobin value of 12.0 to 12.9 g/dL and doubled for a hemoglobin value Ͻ9.0 g/dL ( Table 2) . As with death, the rate of change in hemoglobin level per 6 person-months was not significantly associated with HF hospitalization, after accounting for the absolute level of hemoglobin and other covariates (data not shown).
In multivariable analyses, interaction terms for the hemoglobinϫGFR category were significant for death (PϽ0.001) and hospitalization (PϽ0.001). In analyses stratified by baseline estimated GFR, compared with a hemoglobin value of 13.0 to 13.9 g/dL, there was no significant difference in the adjusted risk of death for a hemoglobin value Ն14.0 g/dL at different levels of kidney function. However, the adjusted relative risk of death with hemoglobin levels Ͻ13.0 g/dL increased in a graded fashion at all levels of GFR, with higher relative risks noted for lower hemoglobin levels at higher levels of GFR (Table 3 ). For HF-related hospitalizations, similar relations were observed with hemoglobin level, except that adjusted relative risks were not materially different across different levels of baseline GFR (Table 4) .
Kidney Function
Compared with a GFR Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 , there was no increased adjusted risk of death for a GFR of 45 to 59 mL · min Ϫ1 · 1.73 m Ϫ2 (Table 2 ). However, the adjusted risk of death was 39% higher for a GFR of 30 to 44 mL · min Ϫ1 · 1.73 m Ϫ2 and increased by 226% for a GFR Ͻ15 mL · min Ϫ1 · 1.73 m Ϫ2 and by 144% for patients receiving dialysis (Table 2) . After adjustment for potential confounders and hemoglobin level, compared with an estimated GFR of Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 , the risk of hospitalization for HF increased by 11% for a GFR of 45 to 59 mL · min Ϫ1 · 1.73 m Ϫ2 and 
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Hemoglobin, GFR, and Heart Failure Outcomesnearly doubled for a GFR of either 15 to 29 mL · min Ϫ1 · 1.73 m Ϫ2 or Ͻ15 mL · min Ϫ1 · 1.73 m Ϫ2 ( Table 2 ). The adjusted risk was only modestly higher for subjects receiving dialysis compared with a GFR Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 .
Analyses Stratified by Systolic Function Status
In the subset of 11 117 subjects with known reduced or preserved systolic function, we observed findings similar to those for the entire cohort. In multivariable analyses, interaction terms for hemoglobinϫLV systolic function status were significant for death (PϽ0.001) and hospitalization (PϽ0.04). Compared with a hemoglobin value of 13.0 to 13.9 g/dL, there were no significant differences in the adjusted risk of death or hospitalization for HF for a hemoglobin value of 15.0 to 16.9 g/dL among subjects with reduced or preserved LV systolic function, whereas a hemoglobin value of 14.0 to 14.9 g/dL was associated with a lower risk of death in those with reduced but not preserved systolic function (Table 5 ). The adjusted risks of adverse outcomes associated with a hemoglobin value Ն17 g/dL were significantly higher only in subjects with preserved systolic function. For a hemoglobin value of Ͻ13.0 to 13.9 g/dL, there were consistent, graded, adjusted higher risks of death and hospitalization of similar magnitude in those with reduced or preserved systolic function (Table 5) . Compared with a GFR Ն60 mL · min Ϫ1 · 1.73 m Ϫ2 , there was no significantly higher adjusted risk of death or hospitalization for a GFR of 45 to 59 mL · min Ϫ1 · 1.73 m Ϫ2 in subjects with reduced or preserved systolic function (Table  5) . However, there were progressively higher adjusted risks as GFR decreased from 30 to 44 mL · min Ϫ1 · 1.73 m Ϫ2 to Ͻ15 mL · min Ϫ1 · 1.73 m Ϫ2 in subjects with reduced or preserved systolic function ( Table 5 ). The adjusted risk of death, but not hospitalization, was increased for maintenance dialysis regardless of systolic function status.
Discussion
We found that very high (Ն17.0 g/dL) and reduced (Ͻ13.0 g/dL) hemoglobin levels as well as reduced kidney function (GFR Ͻ60 mL · min Ϫ1 · 1.73 m Ϫ2 ) were strong predictors of death and hospitalization among adults with HF, even after accounting for known confounders and differential medical therapy. The association with a lower hemoglobin value was a graded one, ranging from 16% and 12% increased adjusted risks of death and hospitalization, respectively, for a hemoglobin value of 12.0 to 12.9 g/dL, to 248% and 99% increased risks, respectively, for a hemoglobin value Ͻ9.0 g/dL. Similarly, the risk of adverse outcomes increased with a progressively lower GFR below an apparent threshold of 45 mL · min Ϫ1 · 1.73 m Ϫ2 . Reduced hemoglobin levels and chronic kidney disease are common and interrelated factors in HF. Lower hemoglobin values in HF can be pseudoanemia due to hemodilution 30 or actual anemia, which can be caused or worsened by various etiologies, such as kidney dysfunction, 6 impaired erythropoietin production or resistance, bone marrow depression from increased levels of proinflammatory cytokines, 31, 32 iron or vitamin deficiencies, 33 malnutrition, 33 and possibly ACE inhibitors. 5, 34 Chronic kidney disease can contribute to the development and exacerbation of HF, and progressive HF contributes to renal hypoperfusion and activation of inflammatory factors, which can lead to the development or worsening of kidney dysfunction.
Low hemoglobin levels, regardless of etiology, have been reported to be associated with lower exercise tolerance 35 and, in most but not all studies, an increased risk of adverse outcomes in HF. 4 -10 Elevated serum creatinine levels 10, 36, 37 and lower creatinine clearance 38, 39 have also been shown to be associated with higher risks of death in HF. Our study extends these previous observations by demonstrating a J-shaped curve for hemoglobin level and the risks of death and hospitalization for HF that is independent of underlying kidney dysfunction, major comorbidity, and longitudinal use of HF therapies. We show that the adjusted risk did not increase until a hemoglobin value Ն17.0 g/dL, whereas there was a steep, graded increase in risk below a hemoglobin value of 13.0 g/dL. Similarly, independent of its contribution to lower hemoglobin levels, a reduced GFR Ͻ45 mL · min Ϫ1 · 1.73 m Ϫ2 was also associated with higher risks in a graded fashion. A recent study reported that a change in hemoglobin level over 12 months was associated with adverse events in a clinical trial HF population. 40 We found that after adjusting for the absolute hemoglobin level during follow-up, patient characteristics, and longitudinal therapy, the rate of change in hemoglobin did not add incremental prognostic information. In addition, within a large study sample with longitudinal hemoglobin measurements, we observed that a lower hemoglobin level was associated with higher relative risks of adverse events at all levels of baseline estimated GFR, which extends previous reports. 5 For the outcome of death, the relative risks associated with lower hemoglobin levels were notably higher at more preserved kidney function, but given the much higher absolute rates of death with a lower GFR, the impact of reduced hemoglobin levels was substantial at all levels of kidney function (Table 3 and Figure 1B ). These associations were also similar in persons with reduced or preserved systolic function.
Whether reduced hemoglobin and chronic kidney disease are causally related to the excess risks of death and hospitalization in HF remains unclear. Postulated mechanisms include increased peripheral and myocardial tissue hypoxia, enhanced levels of proinflammatory cytokines, erythropoietin resistance, accelerated progression of LV hypertrophy and dilatation, abnormal ventricular remodeling, activation of the *Final models included hemoglobin and glomerular filtration rate, as well as age, gender, race/ethnicity, acute myocardial infarction, angina, other diagnosed coronary disease, coronary revascularization, ischemic stroke or transient ischemic attack, peripheral arterial disease, diabetes mellitus, diagnosed hypertension, cancer, thyroid disease, pericarditis, chronic lung or liver disease, HIV infection, valvular heart disease, diagnosed dementia or depression, documented ventricular fibrillation or tachycardia, atrial fibrillation or flutter, left ventricular systolic function status, and use of ACE inhibitors, angiotensin II receptor blockers, diuretics, ␤-blockers, spironolactone, other direct vasodilators, calcium channel blockers, statins, other lipid-lowering therapies, and erythropoietin.
sympathetic nervous system and renin-angiotensin-aldosterone axis, and fluid overload. 3 Clinical trial evidence is also limited for whether treatment of these conditions improves outcomes. Whether increasing hemoglobin can improve clinical outcomes remains controversial. For example, a randomized, open-label trial of 1223 persons with HF and/or coronary disease and receiving hemodialysis assigned to a hematocrit of 42% or 30% by the use of intravenous or subcutaneous epoetin alfa plus iron was terminated early after an interim analysis found that the risk of death was increased in the higher hematocrit group (adjusted relative risk, 1.3; 95% confidence interval, 0.9 to 1.8). 41 In a 3-month randomized, placebo-controlled trial of 23 persons with severe HF (New York Heart Association [NYHA] class III/IV) and hematocrit Ͻ35%, subjects assigned to receive subcutaneous erythropoietin plus oral iron and folate were more likely to exhibit an increase in peak oxygen consumption and exercise duration and improved disease-specific quality of life scores compared with placebotreated subjects. 42 (target hemoglobin, 12.0 or 12.5 g/dL) in a total of 277 patients with medically refractory advanced HF with reduced systolic function and anemia (hemoglobin at entry, 9.5 to 11.5, 10.0 to 11.5, or Ͻ12 g/dL). Receipt of erythropoietin plus intravenous iron was associated with improved LV ejection fraction and NYHA functional class, reduced diuretic doses, and a lower number of subsequent hospitalizations compared with prestudy event rates. 2, [43] [44] [45] However, these studies, though provocative, were of modest sample sizes, included only medically refractory advanced HF, and had less than optimal control groups. We are unaware of any completed clinical trial that has used clinical end points to evaluate a therapeutic strategy targeted at improving GFR in persons with HF. The present study was strengthened by inclusion of a large, diverse, and relatively unselected population with HF diagnosed in both ambulatory and hospital settings and across a broad age spectrum. Our sample size allowed a more detailed evaluation of the level of hemoglobin and estimated GFR at which the risk of adverse outcomes increases. We had longitudinal outpatient information on hemoglobin level and kidney function, as well as updated extensive comorbidity status and use of HF therapies. We also comprehensively captured relevant hospitalizations and deaths.
Our study also has several limitations. A substantial proportion of subjects did not have available information on LV systolic function status, and NYHA severity classification and data on biomarkers such as B-type natriuretic peptide 46 were unavailable. In the subset of persons with known reduced or preserved systolic function, however, results did not differ by systolic function category. We cannot completely rule out residual confounding due to HF severity, although previous studies support the concept that anemia and chronic kidney disease are associated with a poor prognosis regardless of the severity of HF. We had limited details about the possible causes of anemia or renal insufficiency and did not have information on potential mechanisms through which these conditions enhance risk of adverse outcomes, so we cannot determine definitively if they are truly causal or mainly markers of risk. We also relied on automated clinical databases for ascertainment of the presence of comorbidities and use of medications, which may *Final models included hemoglobin and glomerular filtration rate as well as age, gender, race/ethnicity, acute myocardial infarction, angina, other diagnosed coronary disease, coronary revascularization, ischemic stroke or transient ischemic attack, peripheral arterial disease, diabetes mellitus, diagnosed hypertension, cancer, thyroid disease, pericarditis, chronic lung or liver disease, HIV infection, valvular heart disease, diagnosed dementia or depression, documented ventricular fibrillation or tachycardia, atrial fibrillation or flutter, left ventricular systolic function status, and use of ACE inhibitors, angiotensin II receptor blockers, diuretics, ␤-blockers, spironolactone, other direct vasodilators, calcium channel blockers, statins, other lipid-lowering therapies, and recombinant erythropoietin.
have led to some misclassification. Our study was conducted within an insured population in northern California, but we believe that our findings are generalizable to other healthcare settings and uninsured persons, given the broad spectrum of HF and the diverse nature and large size of the studied population.
In conclusion, anemia, polycythemia, and chronic kidney disease are independent predictors of mortality and excess hospitalizations in patients with HF with or without reduced LV systolic function. Given that low hemoglobin levels are common in HF and modifiable through the use of recombinant erythropoietin and/or iron therapy and because erythropoietin may have other favorable cardiovascular effects, 47 large, randomized, controlled trials are needed to determine whether a low hemoglobin level is a modifiable risk factor for adverse clinical outcomes in this high-risk population.
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